Patents Examined by Lorraine Spector
  • Patent number: 9770170
    Abstract: The present invention relates generally to the diagnosis, treatment, and monitoring of Chronic Inflammatory Response Syndrome (CIRS), kits for use in the methods, and pharmaceutical compositions for use in the methods of treatment. The invention specifically relates to the diagnosis, treatment and monitoring of CIRS through a comprehensive approach comprising an assessment of a subject for case definition parameters and a proteogenomic analysis. The proteogenomic analysis for the diagnosis, treatment, and monitoring of CIRS is based on identifying proteins and/or genes that are differentially expressed in subjects suffering from CIRS compared to healthy subjects.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: September 26, 2017
    Inventors: Ritchie Shoemaker, Jimmy Ryan
  • Patent number: 9764078
    Abstract: Some aspects of the invention include methods of treating a patient who has or is at risk of developing kidney disease, methods of selecting a suitable regimen for the prevention or treatment of kidney disease, and to methods of monitoring the effectiveness of a treatment regimen for the prevention or treatment of kidney disease. Other aspects of the invention include medical uses of a binding partner for an anti-IQCJ antibody, and methods of preventing or treating kidney disease in a subject using such binding partners. Still other aspects of the invention include devices for the extracorporeal treatment of a patient's blood.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: September 19, 2017
    Assignee: The University of Manchester
    Inventor: Paul E. C. Brenchley
  • Patent number: 9750804
    Abstract: A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against ENO1. The antagonist binds ENO1 and inhibits ENO1 plasminogen receptor activity. The antagonist may be an anti-human ENO1 antibody, or an scFv, Fab, or F(ab)2 fragment thereof, that specifically binds to human ENO1 (GenBank: AAH50642.1) for the treatment of an inflammatory disease or an immune disorder, which may be multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic Lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, type 1 diabetes mellitus, artherosclerosis or osteoporosis.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: September 5, 2017
    Assignees: Development Center for Biotechnology, National Health Research Institutes
    Inventors: Shih-Chong Tsai, Mingl Chang, Ta-Tung Yuan, Shih-Chi Tseng, Shyi-Jou Chen, Wei-Tso Chia, Hsin-Yun Wang, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
  • Patent number: 9708409
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: July 18, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Patent number: 9689043
    Abstract: The present invention relates to a method for predicting the probability of muscle-invasive bladder cancer (MIBC) recurrence or metastasis, a method for providing information on a personalized medicine of MIBC, and a pharmaceutical composition for treating MIBC, containing S100A9 and EGFR inhibitors and cisplatin as active ingredients. According to the present invention, it is possible to accurately predict a prognosis after chemotherapy of an MIBC patient, to provide information on cisplatin sensitivity in the provision of a personalized medicine for chemotherapy of an MIBC patient, and to increase the cisplatin sensitivity of an MIBC patient by concomitantly administering S100A9 and EGFR inhibitors together with a conventional cisplatin.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: June 27, 2017
    Assignee: Chungbuk National University Industry-Academic Cooperation Foundation
    Inventors: Wun-Jae Kim, Seok-Joong Yun, Won-Tae Kim
  • Patent number: 9518111
    Abstract: The present invention relates to pharmaceutical compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: December 13, 2016
    Assignee: Immunex Corporation
    Inventors: Wayne Richard Gombotz, Richard L. Remmele, Jr.
  • Patent number: 9468685
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 18, 2016
    Assignee: RATIOPHARM GMBH
    Inventors: Walter Hinderer, Heinz Lubenau
  • Patent number: 9458211
    Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: October 4, 2016
    Assignee: Molecular Partners AG
    Inventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
  • Patent number: 8440196
    Abstract: A preventive or therapeutic agent for pancreatitis said agent comprising as an active ingredient an interleukin-6 (IL-6) antagonist such as an antibody directed against IL-6 receptor.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: May 14, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Akihiro Funakoshi, Kyoko Miyasaka
  • Patent number: 8399250
    Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: March 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. De Sauvage
  • Patent number: 8357513
    Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
    Type: Grant
    Filed: February 15, 1994
    Date of Patent: January 22, 2013
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. De Sauvage
  • Patent number: 8278099
    Abstract: Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: October 2, 2012
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. de Sauvage
  • Patent number: 8252000
    Abstract: A femoral condyle cutting and shaping device includes a first bone shaping and cutting tool and at least one assistant shaft which are mounted in a sliding gearbox; at least one driven shaft mounted in a sliding gearbox; a first connecting member and a second connecting member, with one end of the first connecting member joining with one end of the second connecting member so as to form a hinge fitting; at least one other bone shaping and cutting tool mounted on the relevant driven shaft; an adjusting mechanism, which is connected with one driven shaft to change the relative position between the first bone shaping and cutting tool and the at least one other bone shaping and cutting tool. A bone shaping and cutting tool is also disclosed, which has flat or helical structure.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: August 28, 2012
    Assignee: Beijing Montagne Medical Device, Co. Ltd.
    Inventor: Ximing Zhou
  • Patent number: 8241899
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: August 14, 2012
    Assignee: Centocor, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 8241900
    Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: August 14, 2012
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. De Sauvage
  • Patent number: 8192955
    Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: June 5, 2012
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. De Sauvage
  • Patent number: 8193323
    Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: June 5, 2012
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. De Sauvage
  • Patent number: 8182814
    Abstract: The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: May 22, 2012
    Assignees: CSL Limited, Yale University
    Inventors: Manuel Baca, Andrew Donald Nash, Jack A. Elias
  • Patent number: 8183225
    Abstract: The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A2A receptor, in particular, an agonist of an adenosine A2A receptor. The invention also extends to pharmaceutical compositions comprising such an agent that modulates an adenosine receptor such as an adenosine A2A agonist and to prosthetic devices containing such an agent that modulates an adenosine receptor such as an A2A agonist on one or more surfaces or within the prosthetic device such as, for example, suspended in the cement forming the prosthetic device.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: May 22, 2012
    Assignee: New York University
    Inventors: Bruce N. Cronstein, Zhong Sheng Peng
  • Patent number: 8178107
    Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: May 15, 2012
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. De Sauvage